AMG 162

Known as: 162, AMG, AMG-162 
 

Topic mentions per year

Topic mentions per year

2004-2016
012320042016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
OBJECTIVES To evaluate efficacy and safety of three different regimens of denosumab, a fully human monoclonal antibody to… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 4
  • figure 3
Is this relevant?
Review
2011
Review
2011
INTRODUCTION Denosumab, a fully human monoclonal antibody, targets the receptor activator of nuclear factor-kappaB (RANK) ligand… (More)
Is this relevant?
2008
2008
Denosumab (AMG 162) is an investigational fully human monoclonal antibody with a high affinity and specificity for receptor… (More)
Is this relevant?
Review
2006
Review
2006
Receptor activator of nuclear factor-kappaB ligand (RANKL) is a cytokine member of the tumour necrosis factor family that is the… (More)
Is this relevant?
Review
2005
Review
2005
RANKL is an essential factor for osteoclastogenesis. Amgen research group has developed AMG 162, a fully human monoclonal… (More)
Is this relevant?
Review
2005
Review
2005
Bone health is an increasingly important concern in breast cancer survivors because in postmenopausal women, bone-sparing… (More)
Is this relevant?
Review
2005
Review
2005
The intended therapeutic effect of gonadotropin-releasing-hormone (GnRH) agonists is hypogonadism, which is a leading cause of… (More)
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
Highly Cited
2004
Highly Cited
2004
UNLABELLED The safety and bone antiresorptive effect of a single subcutaneous dose of AMG 162, a human monoclonal antibody to… (More)
Is this relevant?
2004
2004
8106 Background: RANKL is an essential osteoclastic differentiation/activation factor. AMG 162 PK and PD were evaluated in a… (More)
Is this relevant?